Castro-Rodriguez JA, et al. - Via searching four electronic databases, researchers assessed the risk of invasive pneumococcal disease (IPD) or pneumonia among children with asthma after the introduction of pneumococcal conjugate vaccines (PCVs). For this investigation, they chose all cohorts or case-control studies of IPD and pneumonia in populations who already received PCV (largely 7-valent pneumococcal conjugate vaccine), but not 23-valent pneumococcal polysaccharide, in which contributors reported data for children with asthma and in which healthy controls were involved, without language restriction. According to results, five studies met criteria of inclusion; of these, three retrospective cohorts (∼26 million person-years) and one case-control study (N = 3,294 children) qualified for the meta-analysis. The authors discovered that asthmatic children continue to have a higher risk of IPD compared with those without asthma despite PCV vaccination. More research is needed in children with asthma, regardless of their use of oral steroids, to determine the need for supplemental 23-valent pneumococcal polysaccharide vaccination.